REFERENCES
1. Iyanagi T. Molecular mechanism of phase I and phase II drug‐metabolizing enzymes: implications for detoxification. Int Rev Cytol. 2007;260:35-112.
2. Miners JO, Polasek TM, Hulin JA, Rowland A, Meech R. Drug-drug interactions that alter the exposure of glucuronidated drugs: scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance. Pharmacol Ther. 2023;248:108459.
3. Allain EP, Rouleau M, Lévesque E, Guillemette C. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br J Cancer. 2020;122:1277-87.
4. Meech R, Hu DG, McKinnon RA, et al. The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol Rev. 2019;99:1153-222.
5. Hulshof EC, Deenen MJ, Nijenhuis M, et al. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. Eur J Hum Genet. 2023;31:982-7.
6. Innocenti F, Iyer L, Ramírez J, Green MD, Ratain MJ. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 2001;29:686-92.
7. Zhang W, Gou P, Dupret JM, Chomienne C, Rodrigues-Lima F. Etoposide, an anticancer drug involved in therapy-related secondary leukemia: enzymes at play. Transl Oncol. 2021;14:101169.
8. Ansaar R, Meech R, Rowland A. A physiologically based pharmacokinetic model to predict determinants of variability in epirubicin exposure and tissue distribution. Pharmaceutics. 2023;15:1222.
9. Herzog N, Katzenberger N, Martin F, Schmidtke KU, K JH. Generation of cytochrome P450 3A4-overexpressing HepG2 cell clones for standardization of hepatocellular testosterone 6β-hydroxylation activity. J Cell Biotechnol. 2015;1:15-26.
10. Herzog N, Hansen M, Miethbauer S, et al. Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures. Cell Biol Int. 2016;40:341-53.
11. Burkard A, Dähn C, Heinz S, et al. Generation of proliferating human hepatocytes using Upcyte® technology: characterisation and applications in induction and cytotoxicity assays. Xenobiotica. 2012;42:939-56.
12. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-81.
13. Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.
14. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos. 2008;36:1461-4.
15. Alvarellos M, Guillemette C, Altman RB, Klein TE. PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2018;28:127-37.
16. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33:1729-39.
17. Tang W. The metabolism of diclofenac - enzymology and toxicology perspectives. Curr Drug Metab. 2003;4:319-29.
18. Kathawala RJ, Gupta P, Ashby CR Jr, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1-17.
19. Fujita K, Sugiyama M, Akiyama Y, Ando Y, Sasaki Y. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol. 2011;67:237-41.
20. Lv X, Xia Y, Finel M, Wu J, Ge G, Yang L. Recent progress and challenges in screening and characterization of UGT1A1 inhibitors. Acta Pharm Sin B. 2019;9:258-78.
21. Alam A, Locher KP. Structure and mechanism of human ABC transporters. Annu Rev Biophys. 2023;52:275-300.
22. Sajid A, Rahman H, Ambudkar SV. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer. 2023;23:762-79.
23. Shen G, Li S, Zhu Y, et al. Recent progress in topoisomerase inhibitors as anticancer agents: research and design strategies for Topo I and II inhibitors via structural optimization. Bioorg Chem. 2025;165:109040.
24. Hofman J, Malcekova B, Skarka A, Novotna E, Wsol V. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol. 2014;278:238-48.
25. Hofman J, Vagiannis D, Chen S, Guo L. Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chem Biol Interact. 2021;340:109448.
26. Li W, Chen YN, Chen YY, et al. Inhibition of UGT1A1*1 and UGT1A1*6 catalyzed glucuronidation of SN-38 by silybins. Chem Biol Interact. 2022;368:110248.
27. Li W, Xing Y, Liu Y. Inhibition of SN-38 glucuronidation by gefitinib and its metabolite. Cancer Chemother Pharmacol. 2015;75:1253-60.
28. Leylek O, Honeywell ME, Lee MJ, Hemann MT, Ozcan G. Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy. Gastric Cancer. 2024;27:1201-19.
29. Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007;17:497-504.
31. Personeni N, Giordano L, Michelini A, et al. Implementing pre-therapeutic UGT1A1 genotyping in clinical practice: a real-life study. J Pers Med. 2022;12:204.
32. Tuteja S, Cayabyab MAS, Hoffecker G, et al. Implementation of DPYD and UGT1A1 testing in patients with GI cancer: a prospective, nonrandomized clinical trial. JCO Precis Oncol. 2025;9:e2500086.
33. Raymond E, Fabbro M, Boige V, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol. 2003;14:603-14.
34. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18:452-64.
35. Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther. 2004;75:448-54.
36. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722-7.
37. Trent J, Molimard M. Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. Semin Oncol. 2011;38 Suppl 1:S28-33.
38. Cengiz B, Yumrutas O, Bozgeyik E, et al. Differential expression of the UGT1A family of genes in stomach cancer tissues. Tumour Biol. 2015;36:5831-7.
39. Hu DG, Marri S, Mackenzie PI, Hulin JA, McKinnon RA, Meech R. The expression profiles and deregulation of UDP-glycosyltransferase (UGT) genes in human cancers and their association with clinical outcomes. Cancers. 2021;13:4491.
40. Arai H, Battaglin F, Wang J, et al. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019;81:101912.
41. Reyhanoglu G, Smith T. Irinotecan. StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554441/. [Last accessed on 27 May 2026].
42. Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013;24:1560-7.
43. Ai L, Zhu L, Yang L, et al. Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases. Xenobiotica. 2014;44:320-5.
44. Radujkovic A, Fruehauf S, Zeller WJ, Ho AD, Topaly J. Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells. Cancer Chemother Pharmacol. 2010;66:255-64.
45. Wang Z, Wang X, Wang Z, et al. In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions. Toxicol Lett. 2021;348:10-7.
46. Lv X, Wang Z, Wang Z, et al. Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases. Chem Biol Interact. 2023;381:110574.
47. Zhang N, Liu Y, Jeong H. Drug-drug interaction potentials of tyrosine kinase inhibitors via inhibition of UDP-glucuronosyltransferases. Sci Rep. 2015;5:17778.
48. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009;100:1701-7.
49. Shi Z, Peng XX, Kim IW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007;67:11012-20.
50. Takigawa N, Takeyama M, Kozuki T, et al. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. Oncol Rep. 2007;17:983-7.
51. Meany HJ, Widemann BC, Hinds PS, et al. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2021;68:e29282.
52. Samalin E, Bouché O, Thézenas S, et al. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer. 2014;110:1148-54.
53. Peer CJ, Sissung TM, Kim A, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res. 2012;18:2099-107.
54. Miners JO, Chau N, Rowland A, et al. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia. Biochem Pharmacol. 2017;129:85-95.
55. Tolosa L, Gómez-Lechón MJ, López S, et al. Human upcyte hepatocytes: characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing. Toxicol Sci. 2016;152:214-29.
56. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006;20:163-75.
